Chronic Myeloid Leukemia in Remission
6
1
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Chronic Kidney Disease Patient in Chronic Myloied Leukemia
ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)